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Abstract
Background: Parkinson’s Disease (PD) is a neurodegenerative disease characterized by motor symptoms, but in
which behavioral and cognitive disturbances are also common. Trust, due to its pervasiveness in society, has
become a major research topic in several scientific disciplines. However, empirical evidence for trust behavior in
neurological patients, and specifically for movement disorders such as PD, is missing. Evidence from healthy
subjects, however, indicates that three brain regions are involved in trust perceptions and behavior, namely the
limbic system, basal ganglia, and frontal cortex. PD affects all these brain regions. Therefore, we hypothesized that
PD patients and healthy controls show differences in trust behavior.
Methods: We conducted an experiment using the trust game, an established paradigm to investigate trust
behavior in both patient and healthy populations alike, controlling for risky decision making. Twenty patients
suffering from PD diagnosed according to UK PDS Brain Bank criteria and twenty healthy controls (matched for age,
gender, education, and income) were recruited. We excluded those suffering from clinically relevant
neuropsychiatric comorbidities.
Results: We found that PD patients exhibit significantly lower levels of trust than do healthy controls. Importantly,
our results cannot be explained by lower levels of risk-taking. Moreover, our results indicate that the trust deficit is
independent of medication, disease duration, and severity of motor symptoms.
Conclusion: Application of a standard procedure for measuring trust behavior revealed that PD patients exhibit
lower levels of trust in other humans than do healthy controls. Against this background we make a call for further
research to determine the underlying pathophysiology of reduced trust in PD.
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Background
Parkinson’s Disease (PD) is a chronic and progressive neu-
rodegenerative disease characterized by the motor symp-
toms bradykinesia, rigidity, resting tremor, and impaired
postural reflexes [1], but in which non-motor symptoms
including behavioral and cognitive disturbances are also
common [2].
Trust is a fundamental prerequisite for various kinds of
relationships in both private and public life, is essen-
tial for the functioning of society in general [3, 4],
and has therefore recently become a major research
topic in various scientific disciplines, including psych-
ology (e.g. [5]), economics (e.g. [3]), information systems
research (e.g. [6]), social neuroscience (e.g. [7]), and psych-
iatry (e.g. [8]). Nevertheless, empirical evidence for trust
behavior in neurological patients, and specifically for
movement disorders such as PD, is still missing. This is
problematic given the importance of trust in the patient-
physician relationship and the impact of trust, among
many other variables, on therapy adherence [9], which is
low in PD [10].
Even though several definitions of trust exist, most
concepts conceptualize trust as a belief, expectation, atti-
tude, or behavior. Generally, trust may be defined as a
psychological state comprising the intention to accept
vulnerability based on positive expectations about the
actions of another party (the trustee) [11, 12]. Formally,
trust is therefore the subjective assessment of the prob-
ability that someone will behave in a trustworthy manner
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[13]. Other psychological states are preconditions for
trust, particularly risk perception, substantially regulated
in the amygdala, insular cortex and other parts of the
limbic system [14], because without perceived risk no
trust is needed.
The goal of trusting another individual is to realize a
reward (e.g., through beneficial cooperation), a fact that
explains the importance of the basal ganglia, particularly
the striatum, and the reward system in general, for trust
behavior [15]. Moreover, positive expectations with re-
gard to the future behavior of the trustee are important
in trust situations, and such expectations are often de-
rived through the process of mentalizing (i.e., inferring
other actors’ intentions), which is related to frontal lobe
function (particularly activation in the paracingulate and
the medial prefrontal cortex) [16]. For an interdisciplinary
discussion of trust, see [17]. In line with these conceptual
relationships between trust and risk perception, reward,
and mentalizing, many studies in the neurobiological
stream of research have found the corresponding three
brain regions and their reciprocal connections to be acti-
vated in trust situations, namely the limbic system, basal
ganglia, and the frontal cortex [12, 15, 18, 19].
It is a well-established fact that PD affects several
brain areas, many of which are related to trust. PD
pathologically transforms the limbic system [20], even in
non-demented and non-depressed patients [21], and
leads to pathological functioning of striatal circuits [22].
Additionally, dopaminergic medication has significant
impact on risk perception and decision making in PD
patients shifting decisions to higher risk choices (e.g.
[23, 24]). Frontal executive functions are long known to
be affected in PD (for a recent review, see [25]), and
disturbances in mentalizing abilities have also been re-
ported (for a review, see [26]).
Because of these impairments we hypothesized that a
difference in trust behavior exists between PD patients
and healthy controls. However, current evidence did not
permit us to anticipate the directionality of this hypothe-
sized effect. On the one hand, as a result of PD patients’
deficiencies in brain regions associated with trust (limbic
system, basal ganglia, frontal cortex), such patients could
be expected to exhibit lower levels of trust behavior than
healthy controls. On the other hand, as a result of
the known positive correlation between dopamine and
trust (for a review, see [12]) and the fact that we
planned to test patients taking anti-Parkinson medi-
cation in order to simulate real-life clinical settings,
patients’ trust behavior might be elevated under
treatment.
Against this background, we formulated the following
hypothesis, which we tested in a laboratory experiment:




All patients suffering from PD who fulfilled strict diag-
nostic criteria (UK PDS Brain Bank [27]), were right-
handed, Caucasian, and had no psychiatric comorbidities
in their history were considered for enrollment in the
order of presentation at the Movement Disorders Out-
patient Clinic. In an opt-out approach, patients were
contacted without their volunteering to take part in the
research and were excluded only if they declared their
unwillingness to participate. Even though patients had
no history of psychiatric comorbidities, we screened
for and in a second step excluded those patients suf-
fering from anxiety, depression, dementia, impulsive-
compulsive disorders and/or apathy at the time of the
experiment in order to minimize possible effects of
these disorders on trust behavior. As a screening tool,
we used the complete version of the Patient Health
Questionnaire (PHQ-D [28]) and the Questionnaire
for Impulsive-Compulsive Disorders (QUIP [29]); ex-
cluded were patients who met pathological criteria.
We screened for dementia according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM IV [30])
using the Mini Mental State Examination (MMSE [31])
and excluded those with an MMSE < 26. Finally, we ap-
plied the Lille Apathy Rating Scale (LARS [32]) to exclude
those suffering from apathy (cut-off point > −15).
Twenty patients ultimately participated in the study
(mean age 72.35 years, SD 9.16, equally gendered). To
better characterize our patient sample we used the
Unified Parkinson's Disease Rating Scale III (UPDRS
[33]) and the Hoehn & Yahr Scale [34] to evaluate
the severity of motor symptoms and recorded anti-
Parkinson, as well as other ongoing medication, disease
duration, age, education, income, and religion using
the corresponding, slightly adjusted National Institute
of Neurological Disorders and Stroke Common Data
Elements [35].
All patients were mildly to moderately ill (mean
UPDRS III score under treatment 19.85, SD 10.59; me-
dian Hoehn & Yahr Stage 2) and received L-DOPA
treatment (mean daily dose 337.5 mg, SD 303). Nine pa-
tients were on supplementary pramipexole medication
(mean daily dose 1.85 mg, SD 1.1), four patients took
ropinirole (mean daily dose 2.5 mg, SD 1.0), and two
rotigotine (mean daily dose 6 mg, SD 2.83). The
mean total L-DOPA equivalent daily dose (L-DOPA +
dopamine agonists) was 448.782 mg (SD 371.443) and
was calculated according to [36]. Four patients re-
ported mild predictable motor fluctuations, three of
whom also mentioned rare dyskinesias (1 %-25 % of
the day). All but three patients had a Schwab and
England Activities of Daily Living Scale score [37] of
80 % or more.
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As control subjects we recruited twenty right-handed,
Caucasians (mean age 68.4 years, SD 10.0, equally gen-
dered) with no history of neurological or psychiatric dis-
ease, with a normal neurological status, and who passed
the same exclusion criteria on MMSE and PHQ-D as
the patient group and were therefore considered healthy.
The controls were usually recruited from among the pa-
tients’ spouses or partners to minimize differences in
age, income, education, or religion, as these factors
might affect trust behavior [38]. Table 1 summarizes the
characteristics of the patient and control groups.
Experimental procedure
Recently, Javor et al. [39] argued that economic games
constitute an appropriate experimental paradigm for
studying behavioral symptoms in neurological diseases.
First, the rules of the game can be understood easily.
Second, the game offers the possibility of quantifying dif-
ferences in actual behavior between patients and healthy
controls, and hence differs from patient or care giver-
based questionnaires with which antecedents of trust
behavior, such as beliefs or attitudes, can be measured.
One specific economic game, the trust game [40] (for
details, see below), is the most frequently used means of
measuring trust in healthy subjects and patients alike,
and has been shown to reliably distinguish trust from
other constructs such as altruism [41]. Using this para-
digm, impaired trust was found for several psychiatric
patient populations (e.g., psychosis and borderline per-
sonality disorder, for a review, see [42]). Importantly,
even though we are not aware of a peer-reviewed scien-
tific study that employed the trust game to study the
trust behavior of PD patients, it has been shown that
non-demented patients suffering from PD are able to
understand the rules of the game (see [43], a study on
altruistic punishment). Thus, the trust game is an appro-
priate experimental paradigm for studying trust behavior
in PD patients.
The study was approved by the ethics committee of
the Federal State Upper Austria. Written consent to par-
ticipate in the study was obtained from all subjects prior
to the experiment. When subjects entered the laboratory
for the experiment, they received written instructions
explaining the rules and payoff structure for the experi-
ment (the instructions are available from the first author
on request). We subsequently checked whether they
understood the information by going through several
hypothetical examples. All included subjects answered
the control questions correctly.
Each round of our version of the trust game involves
two players (the trustor and the trustee). The trustor
plays the first move, the trustee the second move of the
game. This study focused on the trustor, whose role was
played by the participants on a computer. The initial en-
dowment made to the participants was €10. Subjects
were told they would be playing with real money and
that at the end of the experiment they would receive the
mean payoff across all rounds of the game. Thus, the
goal of each round and the entire game was to maximize
the player's payoff. The participants were further told
that they would be playing against human beings,
but actually played against a randomized computer-
generated strategy that simulated a trustee’s behavior.
The trustee role was illustrated with human face images
from an established face database [44, 45] that were
presented on a computer screen. We selected 16 faces
with an emotionally neutral expression in order to exclude
effects of a possible impairment of emotion recognition in
PD patients [46]. All faces had a consistent age range
(between 20 and 30 years) and were equally gendered.
The participants could decide to send any amount of
their initial endowment to the trustee, but had to use
whole numbers between €0 and €10. This decision was
made knowing that this amount would be multiplied by
6 by the investigators and given to the trustee, who
could then decide whether to send money back to the
participant (and, if so, how much). Thus, each subject
saw 16 trustee faces, presented in random order, and
had to decide how much of the €10 endowment to send
to each of the trustees. Randomization of the order of
trustees and trustee behavior was implemented to
minimize effects between the consecutive rounds of the
game. No participant interacted with the same trustee
twice (“one-shot trust games”) in order to rule out
possible effects of reward-based learning on trust game
behavior. We used the monetary amount sent by each
participant as a measure of trust behavior.
After playing the trust game participants were ex-
plained the rules of the Game-of-Dice Task. Risk-taking
Table 1 Characteristics of the patient and control groups
Variable Group
Patients, n = 20
mean ± SD
Controls, n = 20
mean ± SD
Female gender (%) 50 50
Age 72.35 ± 9.16 68.4 ± 10
Income class1 (median) 3 4
Years of education2 10.9 ± 4.03 11.3 ± 5.11
UPDRS III 19.85 ± 10.59 -
Hoehn & Yahr Stage (median) 2 -
MMSE 28.4 ± 1.6 28.95 ± 0.99
LEDD (mg/day) 448,782 ± 371,443 -
Disease duration (months) 39.21 ± 41.82 -
See Endnotes for further information on income and education variables
UPDRS-III Unified Parkinson’s Disease Rating Scale Part III, MMSE Mini Mental
State Examination, LEDD L-DOPA equivalent daily dose of dopamine
agonists + L-DOPA dose
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is considered a standard control condition in trust re-
search, because humans generally take risks less willingly
when the cause of uncertainty is another person, and
therefore it is import to distinguish trust from non-
social risk taking [47]. We included this specific gam-
bling task because it has been extensively used to study
risky decision making in PD patients (e.g. [24, 48–52]).
Furthermore, the Game-of-Dice Task offers, in the con-
text of our experimental design, advantages over other
decision making paradigms, such as the Iowa Gambling
task (IGT), because the IGT includes two mechanisms,
namely decisions under ambiguity in the first trials and
decisions under risk in the latter trials [53, 54]. This
game calls for subjects to maximize their fictive starting
capital of 1,000 cents in 18 dice rolls. One virtual dice
and a shaker cup are used. In each trial subjects have to
guess which number will come up on the next roll. They
can choose one of the various single numbers or a com-
bination of two numbers, three numbers, or four num-
bers. Each choice is associated with specific gains and
losses depending on the probability of the occurrence of
choice: 1,000 cents gain/loss for the choice of a single
number (winning probability 1:6), 500 cents gain/loss for
the choice of two numbers (winning probability of 2:6),
200 cents gain/loss for the choice of three numbers
(winning probability 3:6), and 100 cents gain/loss for
the choice of four numbers (winning probability 4:6).
Choices with winning probabilities of 1:6 and 2:6 are
considered high-risk and disadvantageous, while 3:6
and 4:6 are low-risk and advantageous. This also im-
plies that there are no “intermediate” risk choices.
Thus, the winning probabilities can be easily calcu-
lated, and the amount of risk associated with each
choice is obvious. In the game the dice is rolled and
the particular winning number is presented. Partici-
pants receive feedback (gain or loss) for their decision
in a visual and acoustic way, and the current capital
is shown. The maximum final balance that can be
achieved in the game is 19,000 cents if the subject
always chooses a single number and is successful on
each roll of the dice. The maximum negative balance
is −17,000 cents if the subject always chooses a single
number and is unsuccessful on each roll (the game
description for the Game-of-Dice Task was taken from
[55] and slightly modified to improve comprehension).
We used the number of risky choices (winning probabil-
ities 1:6 and 2:6) in 18 consecutive rounds of the game as
a measure of risk-taking. Actual payment reflecting
the participants’ gain took place at the very end of
the experiment.
Statistical analysis
The statistical analysis was performed with SPSS® and
R®. Considering our formulated hypothesis, we used
two-tailed statistical testing for trust behavior. In
analogy, we chose two-tailed statistical testing for risky
decision making in the Game-of-Dice Task. Further-
more, we determined the effect sizes of our statistical
tests and run a regression analysis to explore the rela-
tionship between trust behavior and other variables of
our study population.
Results
The PD patient and control groups were comparable in
gender, age, income class, education, and religion (see
Table 1), as there was no significant difference in age
(mean patients: 72.35, SD 9.16; mean controls 68.4, SD
10.0; Wilcoxon test; z = −1.189; P = 0.234), income
(classified in 7 categories1; median patients 4; median
controls 3; Wilcoxon test; z = −0.771; P = 0.440), educa-
tion2 (mean education years patients y = 10.9, SD 4.02;
controls y = 11.3, SD 5.11; Wilcoxon test; t = −0.210;
P = 0.833), or religion (all participants were roman-
catholic).
Trust behavior differed significantly between the
patient and control groups (see Fig. 1). Specifically, the
mean investment amount was significantly lower in the
PD patient group than in the control group (mean
patients: €3.43, SD 2.0; mean controls: €5.53, SD 1.56;
Wilcoxon test; z = −3.179, P = 0.001; two-sided test, n = 20
Fig. 1 Results of the trust game (left side) and the Game-of-Dice Task (right side). The diagram on the left shows overall mean investments in the
trust game (trust behavior). The diagram on the right shows the mean number of risky choices in the Game-of-Dice Task (risky decision making)
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in each group), indicating reduced trust in PD. Further
calculation revealed an effect size of r = 0.71, indicating a
strong effect [56].
The Game-of-Dice Task showed a significant differ-
ence in risky decision making between the patient and
control groups (see Fig. 1), with a significantly higher
number of high-risk choices in the PD group (mean
patients: 10.2, SD 3.93; mean controls: 7.05, SD 3.62;
Wilcoxon test; z = −2.596, P = 0.009; two-sided test, n = 20
in each group). The calculated effect size was r = 0.58,
which is considered a strong effect [56].
Gender was not a significant predictor of trust be-
havior in a linear regression model (corrected R2 = 0.388;
β = 0.180; P = 0.210), neither were LEDD, which includes
L-DOPA and dopamine agonists (β = −0.151; P = 0.411),
nor disease duration (β = −0.302; P = 0.765). Moreover,
age and UPDRS III scores came close to being predictors
of trust behavior, but did not reach the level of signifi-
cance (age: β = −0.238; P = 0.078; UPDRS III: β = 0.456;
P = 0.066). The calculated effect size for our regression
study (Cohen’s f2) was f2 = 0.635 [56].
Discussion
The main goal of this study was to empirically test
whether there is a significant difference in trust behavior
between non-demented PD patients without evidence of
significant neuropsychiatric comorbidities (e.g., impulse
control disorder, depression, or apathy) and healthy
controls (matched for age, gender, education, and in-
come). Using the trust game, an established experi-
mental paradigm for studying trust behavior [40], we
found that PD patients exhibit significantly lower
levels of trust than do healthy controls. A direct com-
parison of the results illustrated in Fig. 1 - trust be-
havior (left side) versus risky decision making (right
side) - shows the diametric oppositeness of trust and
risk in our participants. While PD patients exhibit
relatively low levels of trust behavior and relatively
high levels of risk-taking behavior, healthy controls
exhibit the opposite pattern. Low trust can therefore
not be explained by lower levels of risky decision
making in PD, measured with the Game-of-Dice Task,
which is in line with previous evidence [48]. In our
statistical analyses disease duration, medication, and
severity of PD motor symptoms did not reach signifi-
cance in predicting trust behavior.
We see these results as the starting point for future
studies focusing on trust in PD patients. Our data pro-
vide an empirical basis for replication, and for theorizing
in order to derive explanations for the trust deficit ob-
served in PD patients.
As a consequence of our recruitment design (screen-
ing and excluding patients with psychiatric comorbidi-
ties, as well as playing “one-shot” trust games) we can
most likely rule out the possibility that PD patients’
lower trust behavior is a secondary phenomenon of
these co-morbidities, particularly dementia, impulsive-
compulsive disorders, or apathy. Our statistical analyses
further show that dopaminergic medication had no im-
pact on trust behavior of PD patients in the trust game,
but there was a trend for age and severity of PD motor
symptoms under treatment. We cannot rule out that
these variables might have reached significance in a lar-
ger sample.
Trust is based on several other constructs, particularly
risk taking, reward processing and anticipation, and
mentalizing ([14–16], see Background section). Our
study shows that risky decision-making does not explain
lower trust in PD. However, impairments in the reward
and/or theory of mind systems known in PD could be
possible candidates responsible for the altered trust
behavior of PD patients. Independent of the question of
lower trust being a primary or secondary phenomenon,
this is the first report showing lower trust behavior in
patients suffering from PD.
The experimental design of our study entails certain
limitations. First, we acknowledge the fact that the
sample size of our study, even though similar to other
studies in the field (e.g. [43]), might be considered as
relatively small by some readers. However, statistical
power (significance) in hypotheses testing is not only
influenced by sample size, but is also dependent on the
effect size. Thus, our statistically significant results
based on a small sample size imply a large effect size.
Second, even though our behavioral study cannot re-
veal the exact pathophysiology underlying the relatively
low trust behavior of PD patients, it nevertheless offers
potential for theorizing on possible mechanisms. PD af-
fects virtually all brain regions known to be activated in
trust situations ([19–25], see Background section). Thus,
it can be hypothesized that lower trust in PD patients
has a functional-anatomical basis. Obviously, further re-
search is needed to shed light on the exact mechanisms
underlying PD patients’ lowered trust behavior. This is im-
portant for a possible development of effective therapeutic
interventions.
Third, we acknowledge the fact that the trust game
measures trust in an economic context reflecting a
significant proportion of everyday behavior, but re-
sults may not necessarily generalize to other trust
situations.
Fourth, the faces used in our experimental paradigm
had an age range that was lower than the mean age of
our participants. Therefore, it cannot be ruled out that
Parkinson patients do not show a trust deficit in social
interaction with other age groups.
Fifth, even though not uncommon in neuropsycho-
logical research of PD (e.g. [43]), we cannot rule out an
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effect of the recruitment of spouses and family members
of patients as controls on our results.
Moreover, our finding showing that medication and
UPRDS III scores are not predictors of trust behavior
need further empirical validation, ideally based on larger
sample sizes and experimental designs including a com-
parison of trust behavior in off- versus on-periods and
between mildly and severely affected PD patients. Im-
portantly, even if dopaminergic medications were re-
sponsible for the trust deficit, the findings of this study
would still have relevant implications for PD patients,
because PD patients usually experience trust situations
in their everyday life on this medication.
Another fruitful avenue for future research is the in-
vestigation of PD patients’ trustworthiness. Our study
focused on the investor’s role in the trust game, thereby
measuring trust. How PD patients would act in the role
of the trustee (i.e., the party who is given trust and sub-
sequently has to reciprocate, or not) is not known. Thus,
it would be rewarding to study PD patients’ trustworthi-
ness in order to find possible differences in comparison
to healthy controls.
Conclusion
In conclusion, we here show that PD patients exhibit
lower levels of trust as compared to healthy controls.
Now that this has been evidenced on a behavioral level,
further research is needed to explore whether the trust
deficit in PD patients is caused by functional impairment
of relevant brain structures, medication and/or other
pathophysiological conditions. Given that insights into
the neurobiology of PD patients’ trust behavior are the
precondition for the development of effective thera-
peutic interventions, future studies can be expected to
provide rewarding insights.
Endnotes
1Income classes – 1: 0-5,000 Euros per year, 2: 5,001–
10,000 Euros per year, 3: 10,001–25,000 Euros per year,
4: 25,001–50,000 Euros per year, 5: 50,001–100,000
Euros per year, 6: 100,001–200,000 Euros per year, 7:
over 200,000 Euros per year.
2Education – number of years of education starting
from school entry at the age of 6 years, e.g. 12 years
meaning high school graduation.
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